I foolishly was in a crowded indoor location and got COVID (for the third time). I thought about getting Paxlovid. But I figured, heck, I’m healthy and vaccinated; I’ll just tough it out. This turned ...

McDonald Criteria revisions around 30% of patients with atypical clinical symptoms or radiological-only presentation meet MS ...

Takeda Canada Inc. (Takeda) is pleased to announce that Health Canada has expanded the marketing authorization for HyQvia® ...

Dimika V. Cavalier shares details of her long MS diagnosis journey and the eventual acceptance of her new normal.

Lucia Notterpek, Ph.D., professor and senior associate dean for research at the University of Nevada, Reno School of Medicine ...

Immunovant said on Wednesday its drug for a type of chronic autoimmune disease affecting muscles met the main goal of improving some patients' ability to perform daily activities in a late-stage trial ...

Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

Johnson & Johnson's FcRn inhibitor nipocalimab has been awarded fast-track status by the FDA as a treatment for Sjögren's ...

Similar to other recent studies, this Phase 2b study in CIDP begins with a non-placebo controlled run-in (Period 1), during which participants whose disease had worsened during standard of care ...

The FDA bestows a Fast Track designation to Johnson & Johnson's nipocalimab for treating moderate-to-severe Sjogren's disease ...